Thay đổi nồng độ DNA plasma mang đột biến EGFR trong những giờ đầu của liệu pháp nhắm mục tiêu cho phép dự đoán phản ứng khối u ở bệnh nhân ung thư phổi do EGFR điều khiển

citation_journal_title=Sci Transl Med; citation_title=Detection of circulating tumor DNA in early- and late-stage human malignancies; citation_author=C Bettegowda, M Sausen, RJ Leary; citation_volume=6; citation_issue=224; citation_publication_date=2014; citation_pages=224ra24; citation_doi=10.1126/scitranslmed.3007094; citation_id=CR1 citation_journal_title=J Clin Oncol; citation_title=Circulating tumor DNA analysis in patients with cancer: American society of clinical oncology and college of American pathologists joint review; citation_author=JD Merker, GR Oxnard, C Compton; citation_volume=36; citation_issue=16; citation_publication_date=2018; citation_pages=1631-1641; citation_doi=10.1200/JCO.2017.76.8671; citation_id=CR2 citation_journal_title=Cancers (Basel); citation_title=Implementing ctDNA analysis in the clinic: challenges and opportunities in non-small cell lung cancer; citation_author=E Gobbini, A Swalduz, MG Levra; citation_volume=12; citation_issue=11; citation_publication_date=2020; citation_pages=3112; citation_doi=10.3390/cancers12113112; citation_id=CR3 citation_journal_title=J Clin Med; citation_title=The role of the liquid biopsy in decision-making for patients with non-small cell lung cancer; citation_author=D Akhoundova, J Mosquera Martinez; citation_volume=9; citation_issue=11; citation_publication_date=2020; citation_pages=3674; citation_doi=10.3390/jcm9113674; citation_id=CR4 citation_journal_title=Mol Oncol; citation_title=Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients; citation_author=LM Charo, RN Eskander, R Okamura; citation_volume=15; citation_issue=1; citation_publication_date=2021; citation_pages=67-79; citation_doi=10.1002/1878-0261.12791; citation_id=CR5 citation_journal_title=Nat Med; citation_title=Circulating mutant DNA to assess tumor dynamics; citation_author=F Diehl, K Schmidt, MA Choti; citation_volume=14; citation_issue=9; citation_publication_date=2008; citation_pages=985-990; citation_doi=10.1038/nm.1789; citation_id=CR6 citation_journal_title=Ann Oncol; citation_title=Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer; citation_author=J Tie, I Kinde, Y Wang; citation_volume=26; citation_issue=8; citation_publication_date=2015; citation_pages=1715-1722; citation_doi=10.1093/annonc/mdv177; citation_id=CR7 citation_journal_title=Nature; citation_title=Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution; citation_author=C Abbosh, NJ Birkbak, GA Wilson; citation_volume=545; citation_issue=7655; citation_publication_date=2017; citation_pages=446-451; citation_doi=10.1038/nature22364; citation_id=CR8 citation_journal_title=Int J Cancer; citation_title=Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma; citation_author=M Strijker, EC Soer, M Pastena; citation_volume=146; citation_issue=5; citation_publication_date=2020; citation_pages=1445-1456; citation_doi=10.1002/ijc.32586; citation_id=CR9 citation_journal_title=Cancer; citation_title=Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib; citation_author=BS Sorensen, L Wu, W Wei; citation_volume=120; citation_issue=24; citation_publication_date=2014; citation_pages=3896-3901; citation_doi=10.1002/cncr.28964; citation_id=CR10 citation_journal_title=Cancer Res; citation_title=Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer; citation_author=V Anagnostou, PM Forde, JR White; citation_volume=79; citation_issue=6; citation_publication_date=2019; citation_pages=1214-1225; citation_doi=10.1158/0008-5472.CAN-18-1127; citation_id=CR11 citation_journal_title=Lung Cancer; citation_title=Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer; citation_author=EBF Ebert, T McCulloch, KH Hansen; citation_volume=141; citation_publication_date=2020; citation_pages=37-43; citation_doi=10.1016/j.lungcan.2019.12.016; citation_id=CR12 citation_journal_title=EBioMedicine; citation_title=Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study; citation_author=T Fukuhara, H Saito, N Furuya; citation_volume=57; citation_publication_date=2020; citation_doi=10.1016/j.ebiom.2020.102861; citation_id=CR13 citation_journal_title=Clin Cancer Res; citation_title=Is cell death a critical end point for anticancer therapies or is cytostasis sufficient?; citation_author=O Rixe, T Fojo; citation_volume=13; citation_issue=24; citation_publication_date=2007; citation_pages=7280-7287; citation_doi=10.1158/1078-0432.CCR-07-2141; citation_id=CR14 citation_journal_title=Front Oncol; citation_title=Metabolic imaging to assess treatment response to cytotoxic and cytostatic agents; citation_author=NJ Serkova, SG Eckhardt; citation_volume=6; citation_publication_date=2016; citation_pages=152; citation_doi=10.3389/fonc.2016.00152; citation_id=CR15 citation_journal_title=Clin Cancer Res; citation_title=The roles of therapy-induced autophagy and necrosis in cancer treatment; citation_author=RK Amaravadi, CB Thompson; citation_volume=13; citation_publication_date=2007; citation_pages=7271-7279; citation_doi=10.1158/1078-0432.CCR-07-1595; citation_id=CR16 citation_journal_title=Oncol Lett; citation_title=Gefitinib induces lung cancer cell autophagy and apoptosis via blockade of the PI3K/AKT/mTOR pathway; citation_author=ZQ Zhao, ZY Yu, J Li, XN Ouyang; citation_volume=12; citation_issue=1; citation_publication_date=2016; citation_pages=63-68; citation_doi=10.3892/ol.2016.4606; citation_id=CR17 citation_journal_title=Trends Cancer; citation_title=Dark side of cytotoxic therapy: chemoradiation-induced cell death and tumor repopulation; citation_author=MJ Jiang, DN Gu, JJ Dai; citation_volume=6; citation_issue=5; citation_publication_date=2020; citation_pages=419-431; citation_doi=10.1016/j.trecan.2020.01.018; citation_id=CR18 citation_journal_title=Cancer Med; citation_title=Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer; citation_author=H Osumi, E Shinozaki, Y Takeda; citation_volume=8; citation_issue=1; citation_publication_date=2019; citation_pages=408-417; citation_doi=10.1002/cam4.1913; citation_id=CR19 citation_journal_title=Front Genet; citation_title=The use of circulating tumor DNA to monitor and predict response to treatment in colorectal cancer; citation_author=M Reece, H Saluja, P Hollington; citation_volume=10; citation_publication_date=2019; citation_pages=1118; citation_doi=10.3389/fgene.2019.01118; citation_id=CR20 citation_journal_title=Science; citation_title=EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy; citation_author=JG Paez, PA Jänne, JC Lee; citation_volume=304; citation_publication_date=2004; citation_pages=1497-1500; citation_doi=10.1126/science.1099314; citation_id=CR21 citation_journal_title=N Engl J Med; citation_title=Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR; citation_author=M Maemondo, A Inoue, K Kobayashi; citation_volume=362; citation_publication_date=2010; citation_pages=2380-2388; citation_doi=10.1056/NEJMoa0909530; citation_id=CR22 citation_journal_title=Pharmgenomics Pers Med; citation_title=Optimizing response to gefitinib in the treatment of non-small-cell lung cancer; citation_author=P Carotenuto, C Roma, AM Rachiglio; citation_volume=4; citation_publication_date=2011; citation_pages=1-9; citation_doi=10.2147/PGPM.S6626; citation_id=CR23 citation_journal_title=Lancet Oncol; citation_title=Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial; citation_author=R Rosell, E Carcereny, R Gervais; citation_volume=13; citation_issue=3; citation_publication_date=2012; citation_pages=239-246; citation_doi=10.1016/S1470-2045(11)70393-X; citation_id=CR24 citation_journal_title=J Clin Oncol; citation_title=Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations; citation_author=LV Sequist, JC Yang, N Yamamoto; citation_volume=31; citation_issue=27; citation_publication_date=2013; citation_pages=3327-3334; citation_doi=10.1200/JCO.2012.44.2806; citation_id=CR25 citation_journal_title=J Thorac Dis; citation_title=Lazarus response to treatment of patients with lung cancer and oncogenic mutations in the intensive care unit; citation_author=CR Chien, HJ Chen; citation_volume=8; citation_issue=11; citation_publication_date=2016; citation_pages=E1455-E1461; citation_doi=10.21037/jtd.2016.11.110; citation_id=CR26 citation_journal_title=Precis Cancer Med; citation_title=“Lazarus effect” in patient affected by lung adenocarcinoma carrying EGFR, CTNNB1, MET exon 11 and PIK3CA mutations treated with gefitinib; citation_author=N Conci, FG Dalllio, V Comellini; citation_volume=3; citation_publication_date=2020; citation_pages=23; citation_doi=10.21037/pcm-20-32; citation_id=CR27 citation_journal_title=Onkologie; citation_title=High efficacy of first-line gefitinib in non-Asian patients with EGFR-mutated lung adenocarcinoma; citation_author=VM Moiseyenko, SA Procenko, EV Levchenko; citation_volume=33; citation_publication_date=2010; citation_pages=231-238; citation_doi=10.1159/000302729; citation_id=CR28 citation_journal_title=Eur J Cancer; citation_title=New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1); citation_author=EA Eisenhauer, P Therasse, J Bogaerts; citation_volume=45; citation_publication_date=2009; citation_pages=228-247; citation_doi=10.1016/j.ejca.2008.10.026; citation_id=CR29 citation_journal_title=JAMA Oncol; citation_title=Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer; citation_author=AG Sacher, C Paweletz, SE Dahlberg; citation_volume=2; citation_issue=8; citation_publication_date=2016; citation_pages=1014-1022; citation_doi=10.1001/jamaoncol.2016.0173; citation_id=CR30 citation_journal_title=Drug Des Devel Ther; citation_title=Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC); citation_author=M Tiseo, M Bartolotti, F Gelsomino, P Bordi; citation_volume=4; citation_publication_date=2010; citation_pages=81-98; citation_doi=10.2147/dddt.s6594; citation_id=CR31 citation_journal_title=J Thorac Oncol; citation_title=Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer; citation_author=Y Nakamura, K Sano, H Soda; citation_volume=5; citation_publication_date=2010; citation_pages=1404-1409; citation_doi=10.1097/JTO.0b013e3181e59a7b; citation_id=CR32 citation_journal_title=J Thorac Oncol; citation_title=Low-dose gefitinib treatment for patients with advanced non-small cell lung cancer harboring sensitive epidermal growth factor receptor mutations; citation_author=H Satoh, A Inoue, K Kobayashi; citation_volume=6; citation_issue=8; citation_publication_date=2011; citation_pages=1413-1417; citation_doi=10.1097/JTO.0b013e31821d43a8; citation_id=CR33 citation_journal_title=Asian Pac J Cancer Prev; citation_title=Low-dose epidermal growth factor receptor (EGFR)—tyrosine kinase inhibition of EGFR mutation-positive lung cancer: therapeutic benefits and associations between dosage, efficacy and body surface area; citation_author=R Hirano, J Uchino, M Ueno; citation_volume=17; citation_issue=2; citation_publication_date=2016; citation_pages=785-789; citation_doi=10.7314/apjcp.2016.17.2.785; citation_id=CR34 citation_journal_title=Cancer; citation_title=Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: results of a retrospective study; citation_author=E Cayssials, J Torregrosa-Diaz, P Gallego-Hernanz; citation_volume=126; citation_issue=15; citation_publication_date=2020; citation_pages=3438-3447; citation_doi=10.1002/cncr.32940; citation_id=CR35 citation_journal_title=J Clin Oncol; citation_title=The “lazarus response” in treatment-naive, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation; citation_author=CJ Langer; citation_volume=27; citation_issue=9; citation_publication_date=2009; citation_pages=1350-1354; citation_doi=10.1200/JCO.2008.20.4859; citation_id=CR36 citation_journal_title=Mol Cancer Ther; citation_title=Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation; citation_author=M Ono, A Hirata, T Kometani; citation_volume=3; citation_issue=4; citation_publication_date=2004; citation_pages=465-472; citation_id=CR37 citation_journal_title=Cancer Res; citation_title=Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer; citation_author=J Amann, S Kalyankrishna, PP Massion; citation_volume=65; citation_issue=1; citation_publication_date=2005; citation_pages=226-235; citation_id=CR38 citation_journal_title=Oncotarget; citation_title=Gefitinib resistance resulted from STAT3-mediated Akt activation in lung cancer cells; citation_author=K Wu, Q Chang, Y Lu; citation_volume=4; citation_issue=12; citation_publication_date=2013; citation_pages=2430-2438; citation_doi=10.18632/oncotarget.1431; citation_id=CR39 citation_journal_title=Cell; citation_title=Apoptotic pathways: ten minutes to dead; citation_author=DR Green; citation_volume=121; citation_issue=5; citation_publication_date=2005; citation_pages=671-674; citation_doi=10.1016/j.cell.2005.05.019; citation_id=CR40 citation_journal_title=PLoS Med; citation_title=Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics; citation_author=MS Cragg, J Kuroda, H Puthalakath; citation_volume=4; citation_issue=10; citation_publication_date=2007; citation_pages=1681-1689; citation_doi=10.1371/journal.pmed.0040316; citation_id=CR41 citation_journal_title=FEBS J; citation_title=EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors; citation_author=K Takeuchi, F Ito; citation_volume=277; citation_issue=2; citation_publication_date=2010; citation_pages=316-326; citation_doi=10.1111/j.1742-4658.2009.07450.x; citation_id=CR42 citation_journal_title=Cancer Biol Ther; citation_title=EGFR tyrosine kinase inhibition induces autophagy in cancer cells; citation_author=C Fung, X Chen, JR Grandis, U Duvvuri; citation_volume=13; citation_issue=14; citation_publication_date=2012; citation_pages=1417-1424; citation_doi=10.4161/cbt.22002; citation_id=CR43 citation_journal_title=Clin Cancer Res; citation_title=Progression of EGFR-mutant lung adenocarcinoma is driven by alveolar macrophages; citation_author=DH Wang, HS Lee, D Yoon, G Berry, TM Wheeler, DJ Sugarbaker; citation_volume=23; citation_issue=3; citation_publication_date=2017; citation_pages=778-788; citation_doi=10.1158/1078-0432.CCR-15-2597; citation_id=CR44 citation_journal_title=J Immunother Cancer; citation_title=Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors; citation_author=D Ayeni, B Miller, A Kuhlmann; citation_volume=7; citation_issue=1; citation_publication_date=2019; citation_pages=172; citation_doi=10.1186/s40425-019-0643-8; citation_id=CR45 citation_journal_title=Genes Dev; citation_title=Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors; citation_author=K Politi, MF Zakowski, PD Fan; citation_volume=20; citation_issue=11; citation_publication_date=2006; citation_pages=1496-1510; citation_doi=10.1101/gad.1417406; citation_id=CR46 citation_journal_title=Oncotarget; citation_title=EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models; citation_author=A Venugopalan, M Lee, G Niu; citation_volume=7; citation_publication_date=2016; citation_pages=54137-54156; citation_doi=10.18632/oncotarget.11021; citation_id=CR47 citation_journal_title=Int J Cancer; citation_title=EGFR-targeted therapy alters the tumor microenvironment in EGFR-driven lung tumors: implications for combination therapies; citation_author=Y Jia, X Li, T Jiang; citation_volume=145; citation_issue=5; citation_publication_date=2019; citation_pages=1432-1444; citation_doi=10.1002/ijc.32191; citation_id=CR48 citation_journal_title=Asian Pac J Cancer Prev; citation_title=High resolution melting analysis for epidermal growth factor receptor mutations in formalin-fixed paraffin-embedded tissue and plasma free DNA from non-small cell lung cancer patients; citation_author=CW Jing, Z Wang, HX Cao; citation_volume=14; citation_issue=11; citation_publication_date=2014; citation_pages=6619-6623; citation_doi=10.7314/apjcp.2013.14.11.6619; citation_id=CR49 citation_journal_title=Lung Cancer; citation_title=EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291; citation_author=KS Thress, R Brant, TH Carr; citation_volume=90; citation_issue=3; citation_publication_date=2015; citation_pages=509-515; citation_doi=10.1016/j.lungcan.2015.10.004; citation_id=CR50 citation_journal_title=Oncotarget; citation_title=Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02); citation_author=JY Lee, X Qing, W Xiumin; citation_volume=7; citation_issue=6; citation_publication_date=2016; citation_pages=6984-6993; citation_doi=10.18632/oncotarget.6874; citation_id=CR51 citation_journal_title=Oncotarget; citation_title=Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer; citation_author=N Normanno, MG Denis, KS Thress; citation_volume=8; citation_issue=7; citation_publication_date=2017; citation_pages=12501-12516; citation_doi=10.18632/oncotarget.13915; citation_id=CR52 citation_journal_title=Cancers (Basel); citation_title=Evaluation of two EGFR mutation tests on tumor and plasma from patients with non-small cell lung cancer; citation_author=JO Kim, JY Shin, SR Kim; citation_volume=12; citation_issue=4; citation_publication_date=2020; citation_pages=785; citation_doi=10.3390/cancers12040785; citation_id=CR53 citation_journal_title=J Thorac Oncol; citation_title=Evolution and clinical impact of EGFR mutations in circulating free DNA in the BELIEF trial; citation_author=MA Molina-Vila, RA Stahel, U Dafni; citation_volume=15; citation_issue=3; citation_publication_date=2020; citation_pages=416-425; citation_doi=10.1016/j.jtho.2019.11.023; citation_id=CR54 citation_journal_title=Sci Rep; citation_title=Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients; citation_author=A Riediger, S Dietz, U Schirmer; citation_volume=6; citation_publication_date=2016; citation_pages=33505; citation_doi=10.1038/srep33505; citation_id=CR55 citation_journal_title=Cancer Res; citation_title=Early noninvasive detection of response to targeted therapy in non-small cell lung cancer; citation_author=J Phallen, A Leal, BD Woodward; citation_volume=79; citation_issue=6; citation_publication_date=2019; citation_pages=1204-1213; citation_doi=10.1158/0008-5472.CAN-18-1082; citation_id=CR56 citation_journal_title=Clin Cancer Res; citation_title=Monitoring daily dynamics of early tumor response to targeted therapy by detecting circulating tumor DNA in urine; citation_author=H Husain, VO Melnikova, K Kosco; citation_volume=23; citation_issue=16; citation_publication_date=2017; citation_pages=4716-4723; citation_doi=10.1158/1078-0432.CCR-17-0454; citation_id=CR57 citation_journal_title=Oncotarget; citation_title=The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M; citation_author=JS Tseng, KY Su, TY Yang; citation_volume=7; citation_issue=30; citation_publication_date=2016; citation_pages=48059-48069; citation_doi=10.18632/oncotarget.10351; citation_id=CR58 citation_journal_title=Clin Lung Cancer; citation_title=Clinical factors predicting detection of T790M mutation in rebiopsy for EGFR-mutant non-small-cell lung cancer; citation_author=T Kawamura, H Kenmotsu, S Omori; citation_volume=19; citation_issue=2; citation_publication_date=2018; citation_pages=e247-e252; citation_doi=10.1016/j.cllc.2017.07.002; citation_id=CR59 citation_journal_title=Oncol Res Treat; citation_title=EGFR T790M mutation in TKI-naïve clinical samples: frequency, tissue mosaicism, predictive value and awareness on artifacts; citation_author=ED Lavdovskaia, AG Iyevleva, AP Sokolenko; citation_volume=41; citation_issue=10; citation_publication_date=2018; citation_pages=634-642; citation_doi=10.1159/000491441; citation_id=CR60 citation_journal_title=JAMA Oncol; citation_title=Effect of osimertinib and bevacizumab on progression-free survival for patients with metastatic egfr-mutant lung cancers: a phase 1/2 single-group open-label trial; citation_author=HA Yu, AJ Schoenfeld, A Makhnin; citation_volume=6; citation_issue=7; citation_publication_date=2020; citation_pages=1048-1054; citation_doi=10.1001/jamaoncol.2020.1260; citation_id=CR61 citation_journal_title=Lancet Oncol; citation_title=Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial; citation_author=K Nakagawa, EB Garon, T Seto; citation_volume=20; citation_issue=12; citation_publication_date=2019; citation_pages=1655-1669; citation_doi=10.1016/S1470-2045(19)30634-5; citation_id=CR62